Tirzepatide (Choose Option)

Tirzepatide is a dual incretin receptor agonist that activates both GLP-1 and GIP pathways to support advanced appetite control, improved metabolic function, and enhanced insulin sensitivity. It’s widely researched for its strong weight-management potential and impact on metabolic efficiency.

What It Supports

• Major reductions in appetite and food cravings
• Better adherence to caloric deficit
• Improved insulin sensitivity and blood-sugar control
• Fat-oxidation and metabolic flexibility
• Support for long-term weight-loss research outcomes

How It Works
Tirzepatide’s dual-agonist mechanism amplifies the body’s natural incretin response:

• GLP-1 → Satiety and slower gastric emptying
• GIP → Enhances insulin activity & meal-based glucose control

Together, these signals promote fewer calories consumed — and more body fat used as fuel.

Ideal Research Applications

• Weight-management protocol testing
• Obesity and insulin-resistance studies
• Appetite and hunger-signaling pathways
• Dietary-behavior modification research

For Research Use Only
Not approved by the FDA for medical use. Not intended to diagnose, treat, cure, or prevent any disease. Laboratory research only.